Organophosphate And Carbamate Poisoning – Pipeline Review, H2 2013

41 pages report Published in
Pharmaceuticals
Publisher: Global Markets Direct

arrowFor This Report

Organophosphate And Carbamate Poisoning – Pipeline Review, H2 2013

Summary

Global Markets Direct’s, ‘Organophosphate And Carbamate Poisoning – Pipeline Review, H2 2013’, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Organophosphate And Carbamate Poisoning, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Organophosphate And Carbamate Poisoning. Organophosphate And Carbamate Poisoning – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– A snapshot of the global therapeutic scenario for Organophosphate And Carbamate Poisoning.

– A review of the Organophosphate And Carbamate Poisoning products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

– Coverage of products based on various stages of development ranging from discovery till registration stages.

– A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

– Coverage of the Organophosphate And Carbamate Poisoning pipeline on the basis of route of administration and molecule type.

– Key discontinued pipeline projects.

– Latest news and deals relating to the products.

Reasons to buy

– Identify and understand important and diverse types of therapeutics under development for Organophosphate And Carbamate Poisoning.

– Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

– Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

– Devise corrective measures for pipeline projects by understanding Organophosphate And Carbamate Poisoning pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Organophosphate And Carbamate Poisoning Overview 6

Therapeutics Development 7

An Overview of Pipeline Products for Organophosphate And Carbamate Poisoning 7

Organophosphate And Carbamate Poisoning Therapeutics under Development by Companies 9

Organophosphate And Carbamate Poisoning Therapeutics under Investigation by Universities/Institutes 10

Mid Clinical Stage Products 11

Comparative Analysis 11

Early Clinical Stage Products 12

Comparative Analysis 12

Discovery and Pre-Clinical Stage Products 13

Comparative Analysis 13

Organophosphate And Carbamate Poisoning Therapeutics - Products under Development by Companies 14

Organophosphate And Carbamate Poisoning Therapeutics - Products under Investigation by Universities/Institutes 15

Companies Involved in Organophosphate And Carbamate Poisoning Therapeutics Development 16

Baxter International Inc. 16

PharmAthene, Inc. 17

Protalix BioTherapeutics, Inc. 18

MicroDose Therapeutx, Inc. 19

Organophosphate And Carbamate Poisoning - Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Drug Profiles 25

PRX-105 - Drug Profile 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

MDT-011 - Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

atropine sulfate - Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Plasma Derived Butyrylcholinesterase - Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Organophosphate Antidote CR - Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Second Generation Protexia - Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Organophosphate And Carbamate Poisoning Therapeutics - Drug Profile Updates 32

Organophosphate And Carbamate Poisoning Therapeutics - Dormant Products 34

Organophosphate And Carbamate Poisoning - Product Development Milestones 35

Featured News & Press Releases 35

Apr 17, 2013: PharmAthene's Recombinant Butyrylcholinesterase Successfully Targets Nerve Agents In In-Vitro Study 35

Jun 07, 2011: MicroDose Therapeutx Announces Successful Completion Of Phase I Pilot Study Of Inhaled Atropine As Antidote To Combat Effects Of Nerve Agent Poisoning 35

Jan 04, 2011: Protalix To Present PRX-105 Data At BARDA Industry Day 36

Jun 08, 2010: Protalix Completes Phase I Clinical Trial For PRX-105 37

Sep 23, 2009: MicroDose Therapeutx Announces Initiation Of Phase I Study With Inhaled Atropine As Antidote To Combat Effects Of Nerve Agent Poisoning 37

May 15, 2007: King Pharmaceuticals AtroPen Receives DHS Safety Act Designation 38

Jun 20, 2003: King Pharmaceuticals Atropen Approved By FDA 39

Appendix 40

Methodology 40

Coverage 40

Secondary Research 40

Primary Research 40

Expert Panel Validation 40

Contact Us 41

Disclaimer 41



List of Tables

Number of Products Under Development for Organophosphate And Carbamate Poisoning, H2 2013 7

Products under Development for Organophosphate And Carbamate Poisoning - Comparative Analysis, H2 2013 8

Number of Products under Development by Companies, H2 2013 9

Number of Products under Investigation by Universities/Institutes, H2 2013 10

Comparative Analysis by Mid Clinical Stage Development, H2 2013 11

Comparative Analysis by Early Clinical Stage Development, H2 2013 12

Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 13

Products under Development by Companies, H2 2013 14

Products under Investigation by Universities/Institutes, H2 2013 15

Baxter International Inc., H2 2013 16

PharmAthene, Inc., H2 2013 17

Protalix BioTherapeutics, Inc., H2 2013 18

MicroDose Therapeutx, Inc., H2 2013 19

Assessment by Monotherapy Products, H2 2013 20

Assessment by Stage and Route of Administration, H2 2013 22

Assessment by Stage and Molecule Type, H2 2013 24

Organophosphate And Carbamate Poisoning Therapeutics - Drug Profile Updates 32

Organophosphate And Carbamate Poisoning Therapeutics - Dormant Products 34



List of Figures

Number of Products under Development for Organophosphate And Carbamate Poisoning, H2 2013 7

Products under Development for Organophosphate And Carbamate Poisoning - Comparative Analysis, H2 2013 8

Products under Development by Companies, H2 2013 9

Products under Investigation by Universities/Institutes, H2 2013 10

Mid Clinical Stage Products, H2 2013 11

Early Clinical Stage Products, H2 2013 12

Discovery and Pre-Clinical Stage Products, H2 2013 13

Assessment by Monotherapy Products, H2 2013 20

Assessment by Route of Administration, H2 2013 21

Assessment by Stage and Route of Administration, H2 2013 22

Assessment by Molecule Type, H2 2013 23

Assessment by Stage and Molecule Type, H2 2013 24

Related Reports

  • Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) – Pipeline Review, H2 2014Global Markets Direct's, ‘Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline Review, H2 2014', provides an overview of the Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action […]
  • Infections Caused By Picornaviridae – Pipeline Review, H1 2014Global Markets Direct's, ‘Infections Caused By Picornaviridae Pipeline Review, H1 2014', provides an overview of the Infections Caused By Picornaviridae's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Infections Caused By Picornaviridae, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest […]
  • Opioid Induced Side Effects – Pipeline Review, H1 2014Global Markets Direct's, ‘Opioid Induced Side Effects Pipeline Review, H1 2014', provides an overview of the Opioid Induced Side Effects's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Opioid Induced Side Effects, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured […]
  • Functional (Non Ulcer) Dyspepsia – Pipeline Review, H2 2014Global Markets Direct's, ‘Functional (Non Ulcer) Dyspepsia Pipeline Review, H2 2014', provides an overview of the Functional (Non Ulcer) Dyspepsia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Functional (Non Ulcer) Dyspepsia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, […]
  • Ventilator Associated Pneumonia (VAP) – Pipeline Review, H2 2014Global Markets Direct's, ‘Ventilator Associated Pneumonia (VAP) Pipeline Review, H2 2014', provides an overview of the Ventilator Associated Pneumonia (VAP)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ventilator Associated Pneumonia (VAP), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with […]